REVIVA PHARMACEUTICALS HOLDINGS, INC. short interest in 2020
In 2020, REVIVA PHARMACEUTICALS HOLDINGS, INC.'s disclosed short interest ran from 1.82% of shares outstanding on 15 Jan 2020 to 2.94% on 13 Nov 2020, a change of +1.12 percentage points. The year's high was 2.94% on 15 Jul 2020 and its low 1.81% on 14 Feb 2020, averaging 2.33% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 999.99 days on 15 Oct 2020. Full history: REVIVA PHARMACEUTICALS HOLDINGS, INC..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2020 in figures
- Start of year
- 1.82% (15 Jan 2020)
- End of year
- 2.94% (13 Nov 2020)
- Change
- +1.12 pp
- High
- 2.94% (15 Jul 2020)
- Low
- 1.81% (14 Feb 2020)
- Average
- 2.33%
- Highest days to cover
- 999.99 (15 Oct 2020)
- SEC filings marked
- 4
Every report in 2020
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2020 | 1.82% | 882.48 | 10-Q filed |
| 31 Jan 2020 | 1.82% | 210.71 | |
| 14 Feb 2020 | 1.81% | 4.43 | |
| 28 Feb 2020 | 1.81% | 21.23 | |
| 13 Mar 2020 | 1.81% | 3.27 | |
| 31 Mar 2020 | 1.84% | 2.16 | |
| 15 Apr 2020 | 1.86% | 20.60 | |
| 30 Apr 2020 | 1.86% | 18.87 | |
| 15 May 2020 | 1.96% | 4.98 | 10-K filed |
| 29 May 2020 | 1.96% | 6.13 | |
| 15 Jun 2020 | 1.98% | 242.13 | |
| 30 Jun 2020 | 1.97% | 26.42 | |
| 15 Jul 2020 | 2.94% | 19.83 | 10-Q filed |
| 31 Jul 2020 | 2.93% | 4.83 | |
| 14 Aug 2020 | 2.92% | 39.30 | |
| 31 Aug 2020 | 2.92% | 6.95 | |
| 15 Sep 2020 | 2.92% | 7.16 | |
| 30 Sep 2020 | 2.92% | 22.34 | |
| 15 Oct 2020 | 2.93% | 999.99 | 10-Q filed |
| 30 Oct 2020 | 2.93% | 18.82 | |
| 13 Nov 2020 | 2.94% | 4.16 |
See also: REVIVA PHARMACEUTICALS HOLDINGS, INC.'s full history · most shorted US stocks of 2020 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.